Therapy strategies for Usher syndrome Type 1C in the retina.
Mainz, Germany. In Adv Exp Med Biol, 2013
Three clinical subtypes (USH1-USH3) are defined according to the severity of the hearing impairment, the presence or absence of vestibular dysfunction and the age of onset of retinitis pigmentosa (RP).
Targeted next generation sequencing for molecular diagnosis of Usher syndrome.
Valencia, Spain. In Orphanet J Rare Dis, 2013
METHODS: A custom HaloPlex panel for Illumina platforms was designed to capture all exons of the 10 known causative Usher syndrome genes (MYO7A, USH1C, CDH23, PCDH15, USH1G, CIB2, USH2A, GPR98, DFNB31 and CLRN1), the two Usher syndrome-related genes (HARS and PDZD7) and the two candidate genes VEZT and MYO15A.
[Molecular updates on Usher syndrome].
Montpellier, France. In J Fr Ophtalmol, 2005
Type III (USH3) is characterized by a progressive loss of hearing and is found more frequently among Finnish patients.
Genetic heterogeneity in Usher syndrome.
New Orleans, United States. In Am J Med Genet A, 2004
Three clinical types of Usher syndrome have been described: USH1 patients have severe to profound congenital hearing loss, vestibular dysfunction, and retinal degeneration beginning in childhood, those with USH2 have moderate to severe congenital hearing loss, normal vestibular function, and later onset of retinitis pigmentosa, and USH3 patients have progressive hearing loss, which distinguishes them from the other two types.